EUVIMEDEUVIMED entdecken
Crossref

In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy

Haofei Hong, Kun Zhou, Han Lin, Yanchun Li, Zhimeng Wu iD

Chemistry – A European Journal · 2025

DOI: 10.1002/chem.202403539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Haofei Hong und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, Chin…. Hauptthemen laut MEDLINE: Immunotherapy, Rituximab, Polyethylene Glycols, Rhamnose. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancing the Fc effector functions of monoclonal antibodies (mAbs) is a proven strategy for improving cancer immunotherapy. In this study, we present a novel pre‐targeting approach that integrates host‐guest chemistry with an antibody‐recruiting concept to create mAbs with superior effector functions. Using rituximab (RTX), a clinically approved anti‐CD20 mAb, as our model, we modified RTX by conjugating it with adamantane (Ada) derivatives and various polyethylene glycol (PEG) linkers to produce RTX‐Ada conjugates. These conjugates effectively formed RTX‐rhamnose (Rha) complexes in situ through self‐assembly, driven by host‐guest interactions with Rha‐modified β‐cyclodextrin. This mechanism successfully redirected endogenous anti‐Rha antibodies to target cells, enhancing the availability of Fc domains for improved effector functions, including complement‐dependent cytotoxicity (CDC). A structure‐activity relationship study indicated that the potency of these in situ complexes was significantly influenced by the length of the PEG linker used; shorter PEG linkers correlated with higher CDC activity. Given the variability in endogenous antibody levels among individuals, this strategy presents a flexible and promising platform for enhancing the efficacy of mAb‐based cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyRituximabPolyethylene GlycolsRhamnoseNeoplasmsHumansAntibodies, MonoclonalAdamantaneCell Line, TumorStructure-Activity Relationshipbeta-CyclodextrinsImmunoconjugates

Stichwörter der Autor:innen

Cancer immunotherapyFc effector functionMonoclonal antibodyPre-targetingRhamnose

Substanzen

RituximabPolyethylene GlycolsRhamnoseAntibodies, MonoclonalAdamantanebeta-CyclodextrinsImmunoconjugates

Autor:innen und Institutionen

  • The Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, China.

ORCID-Profile: Zhimeng Wu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hong, H., Zhou, K., Lin, H., Li, Y., & Wu, Z. (2025). In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy. Chemistry – A European Journal. https://doi.org/10.1002/chem.202403539

Vancouver

Hong H, Zhou K, Lin H, Li Y, Wu Z. In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy. Chemistry – A European Journal. 2025. doi:10.1002/chem.202403539

BibTeX
@article{Hong2025,
  author = {Hong, Haofei and Zhou, Kun and Lin, Han and Li, Yanchun and Wu, Zhimeng},
  title = {In Situ Self‐Assembly of Antibody‐Rhamnose Complex as a Pre‐Targeting Strategy for Enhanced Cancer Immunotherapy},
  journal = {Chemistry – A European Journal},
  year = {2025},
  doi = {10.1002/chem.202403539}
}
Kostenlos starten →